The Long Non-Coding BC200 Is a Novel Circulating Biomarker of Parathyroid Carcinoma.
biomarker
brain cytoplasmic RNA 1
epigenetics
long non-coding RNAs
parathyroid
parathyroid carcinoma
Journal
Frontiers in endocrinology
ISSN: 1664-2392
Titre abrégé: Front Endocrinol (Lausanne)
Pays: Switzerland
ID NLM: 101555782
Informations de publication
Date de publication:
2022
2022
Historique:
received:
03
02
2022
accepted:
04
04
2022
entrez:
19
5
2022
pubmed:
20
5
2022
medline:
21
5
2022
Statut:
epublish
Résumé
Long non-coding RNAs (lncRNAs) are an important class of epigenetic regulators involved in both physiological processes and cancer development. Preliminary evidence suggested that lncRNAs could act as accurate prognostic and diagnostic biomarkers. Parathyroid cancer is a rare endocrine neoplasia, whose management represents a clinical challenge due to the lack of accurate molecular biomarkers. Our previous findings showed that human parathyroid tumors are characterized by a different lncRNAs signature, suggesting heterogeneity through the different histotypes. Particularly, we found that the lncRNA BC200/BCYRN1 could represent a candidate biomarker for parathyroid carcinomas (PCas). Here we aimed to extend our preliminary data evaluating whether BC200 could be an accurate non-invasive biomarker of PCas to support the clinical management of patients affected by parathyroid tumors at diagnosis, prognosis and follow-up. To provide a non-invasive point-of-care for parathyroid carcinoma diagnosis and follow-up, we analyzed BC200 expression in patients' serum through digital PCR. Our results show that BC200 counts are higher in serum from patients harboring PCa (n=4) compared to patients with parathyroid adenoma (PAd; n=27). Further, in PAd patients circulating BC200 levels are positively correlated with serum total calcium. Then, we found that BC200 is overexpressed in metastatic PCas (n=4) compared to non-metastatic ones (n=9). Finally, the lncRNA expression in PCa patients' serum drops are reduced after parathyroidectomy, suggesting its possible use in the post-operative setting for patients follow-up. Overall, these findings extend the knowledge on BC200 in parathyroid tumors, supporting its role as a useful biomarker for management of PCa.
Identifiants
pubmed: 35586620
doi: 10.3389/fendo.2022.869006
pmc: PMC9108332
doi:
Substances chimiques
Biomarkers
0
RNA, Long Noncoding
0
long non-coding RNA BC200, human
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
869006Informations de copyright
Copyright © 2022 Morotti, Cetani, Passoni, Borsari, Pardi, Guarnieri, Verdelli, Tavanti, Valenti, Bianco, Ferrero, Corbetta and Vaira.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
J Clin Endocrinol Metab. 2012 Jul;97(7):E1307-15
pubmed: 22544915
Oncotarget. 2017 Dec 21;9(4):4851-4861
pubmed: 29435146
J Clin Endocrinol Metab. 2001 Feb;86(2):485-93
pubmed: 11157996
BMC Cancer. 2019 Oct 23;19(1):994
pubmed: 31646972
Ann Surg Oncol. 2018 Sep;25(9):2535-2540
pubmed: 29971678
J Endocrinol Invest. 2016 Jun;39(6):595-606
pubmed: 27001435
Osteoporos Int. 2019 Jul;30(7):1511-1519
pubmed: 30972448
Int J Biochem Cell Biol. 2018 Jun;99:219-225
pubmed: 29625226
Endocr Relat Cancer. 2014 Aug;21(4):R319-30
pubmed: 24898948
Int J Mol Sci. 2021 Oct 18;22(20):
pubmed: 34681865
Cancer Res. 2013 Aug 1;73(15):4801-9
pubmed: 23774211
J Bone Miner Res. 2020 Dec;35(12):2423-2431
pubmed: 32780442
Genes Chromosomes Cancer. 2011 Sep;50(9):735-45
pubmed: 21638518
J Bone Miner Res. 2008 Dec;23(12):1869-80
pubmed: 19016595
Nat Genet. 2013 Nov;45(11):1392-8
pubmed: 24076601
Eur J Surg Oncol. 2021 Nov;47(11):2768-2773
pubmed: 34229923
Cancer Lett. 2016 May 1;374(2):261-71
pubmed: 26898939
Noncoding RNA Res. 2018 May 22;3(3):131-143
pubmed: 30175286
J Mol Endocrinol. 2012 Jul 26;49(2):115-24
pubmed: 22767050
Endocr Pathol. 2019 Jun;30(2):96-105
pubmed: 31119524
Trends Genet. 2012 Oct;28(10):474-9
pubmed: 22704242
Curr Treat Options Oncol. 2012 Mar;13(1):11-23
pubmed: 22327883
Cell Physiol Biochem. 2018;48(6):2337-2349
pubmed: 30114690
J Investig Med. 2018 Oct;66(7):1055-1063
pubmed: 29967012
Endocr Relat Cancer. 2010 Feb 18;17(1):135-46
pubmed: 19926710
Endocr Pathol. 2022 Mar;33(1):64-89
pubmed: 35175514
Endocr Relat Cancer. 2019 Feb;26(2):163-176
pubmed: 30403657
Endocr Relat Cancer. 2018 Jul;25(7):761-771
pubmed: 29724878
Mol Cells. 2018 Dec 31;41(12):993-999
pubmed: 30590906
J Exp Clin Cancer Res. 2019 Feb 6;38(1):60
pubmed: 30728036
Acta Otolaryngol. 2002 Jun;122(4):448-52
pubmed: 12126006